Results 191 to 200 of about 28,025 (230)
Double-negative T cells in combination with ursodeoxycholic acid ameliorates immune-mediated cholangitis in mice. [PDF]
Zhang C +8 more
europepmc +1 more source
A novel therapy targeting the gut-liver axis for chronic hepatitis B: Ursodeoxycholic acid plus <i>Bifidobacterium</i>. [PDF]
Xun Z +19 more
europepmc +1 more source
Ursodeoxycholic acid alleviates aortic aneurysm and dissection through the intestinal farnesoid X receptor/ceramide synthase 2 axis. [PDF]
Zhang Z +11 more
europepmc +1 more source
Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases. [PDF]
Hu T +5 more
europepmc +1 more source
The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial. [PDF]
Abulitifu Y +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Gastroenterology and Hepatology, 1996
Abstract Ursodeoxycholic acid (UDCA) has recently been combined with interferon (IFN) in the treatment of individuals with chronic hepatitis C. However, whether its addition results in a long‐term favourable response to IFN remains unclear. A prospective randomized trial of IFN alone versus IFN plus UDCA was therefore undertaken in 52 patients with ...
KATSUAKI TANAKA +8 more
openaire +2 more sources
Abstract Ursodeoxycholic acid (UDCA) has recently been combined with interferon (IFN) in the treatment of individuals with chronic hepatitis C. However, whether its addition results in a long‐term favourable response to IFN remains unclear. A prospective randomized trial of IFN alone versus IFN plus UDCA was therefore undertaken in 52 patients with ...
KATSUAKI TANAKA +8 more
openaire +2 more sources

